|Study Description:||The goal of this clinical research study is to compare the effectiveness and |
safety of 2 chemotherapy combinations. Participants on this study will receive
either a standard combination called CHOP (cyclophosphamide,
hydroxydaunorubicin [doxorubicin], oncovin [vincristine], and prednisone), or
an investigational combination called A+CHP. A+CHP is similar to CHOP, but the
patient receives brentuximab vedotin instead of vincristine.
Brentuximab vedotin has 2 parts. The first part is designed to attach to a
protein called CD30. CD30 is found on some normal cells in the body’s immune
system and on some types of MTCL, such as anaplastic large cell lymphoma
(ALCL). The second part of brentuximab vedotin may kill the cancer cells that
the first part targeted.
Cyclophosphamide, doxorubicin, and vincristine are designed to stop cancer
cells from growing and/or dividing, which may cause the cells to die.
Prednisone is a corticosteroid that is similar to a natural hormone made by
your body. Prednisone is often given in combination with other chemotherapy to